You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Type 2 Inflammation

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

Michele Ramien
MD
Michele Ramien

Learning objectives

  • Understand the impact of advanced systemic therapies on atopic dermatitis pathomechanisms, including skin barrier function, microbiome, and neuroanatomy
  • Evaluate the effectiveness of biologic immunomodulators in modifying disease pathophysiology

Description

Explore the concept of using advanced systemic therapies to modify atopic dermatitis pathomechanisms, including skin barrier dysfunction, microbial dysbiosis, and neuroinflammation. Evidence suggests targeted therapies improve skin barrier function, normalize microbiome, and restore neuroanatomy.

Tags
disease backgroundbiologicsmechanism of diseaseexpert insights
MAT-GLB-2402326 - 2.0 - 01/2025

About this expert

Dermatology

Michele Ramien

MD

Clinician-Investigator at the Alberta Children’s Hospital in Calgary, Alberta, Canada

See author’s profile
Michele Ramien

Related resources

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions
Dermatology
Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Dermatology
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Diagnostic Algorithm for Patients Presenting with Wheals and/or Angioedema
Dermatology
interactivity

Diagnostic Algorithm for Patients Presenting with Wheals and/or Angioedema

Tools for Clinical Assessment of Prurigo Nodularis
Dermatology
Infographic

Tools for Clinical Assessment of Prurigo Nodularis

Expert Case Series: The Burden of AD in Pediatric Patients
Dermatology
interactivity

Expert Case Series: The Burden of AD in Pediatric Patients

Type 2 Inflammation as the Common Thread in Multiple Diseases
Type 2 Inflammation
videoanimation

Type 2 Inflammation as the Common Thread in Multiple Diseases

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression
Type 2 Inflammation
expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients
Type 2 Inflammation
expert video

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases

Genetics of Type 2 Inflammation
Type 2 Inflammation
expert video

Genetics of Type 2 Inflammation

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis
Type 2 Inflammation
expert video

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

AD and PN: Commonalities and Differences – A Case Study
Dermatology
expert video

AD and PN: Commonalities and Differences – A Case Study

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression
Type 2 Inflammation
expert video

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression

AAAAI 2023 | Defining Type 2 Inflammation
Type 2 Inflammation
expert video

AAAAI 2023 | Defining Type 2 Inflammation

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD
Type 2 Inflammation
expert video

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children
Type 2 Inflammation
expert video

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan
Type 2 Inflammation
expert video

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan

Type 2 Inflammation Drives Atopic Dermatitis from Infancy to Adulthood
Dermatology
videoanimation

Type 2 Inflammation Drives Atopic Dermatitis from Infancy to Adulthood

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
Dermatology
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview

Differences in Manifestations of Type 2 Inflammatory Diseases
Dermatology
expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

Mast Cells and the Neuroimmune Axis in CSU
Dermatology
expert video

Mast Cells and the Neuroimmune Axis in CSU

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions
Dermatology
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview
Dermatology
expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
Dermatology
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD
Dermatology
expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

The Burden of Atopic Dermatitis in Children and Their Caregivers - Paller
Dermatology
expert video

The Burden of Atopic Dermatitis in Children and Their Caregivers - Paller

The Neuroimmune Axis in Itch: Complex Pathophysiology Driving an Important Clinical Symptom
Dermatology
expert video

The Neuroimmune Axis in Itch: Complex Pathophysiology Driving an Important Clinical Symptom

New Systemic Treatment Options For Children With Atopic Dermatitis - Expert Interview
Dermatology
expert video

New Systemic Treatment Options For Children With Atopic Dermatitis - Expert Interview

Pruritic Dermatoses with a Type 2 Inflammation Component
Type 2 Inflammation
expert video

Pruritic Dermatoses with a Type 2 Inflammation Component

Role of Type 2 Inflammation in Chronic Inflammatory Diseases
Dermatology
expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview
Dermatology
expert video

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 
Dermatology
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis
Dermatology
expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis
Type 2 Inflammation
expert video

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis

Prurigo Nodularis: The Patient Journey
Dermatology
interactivity

Prurigo Nodularis: The Patient Journey

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics
Dermatology
Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

What proportion of patients can achieve control in CRSwNP?
Type 2 Inflammation
expert video

What proportion of patients can achieve control in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Type 2 Inflammation
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Type 2 Inflammation
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Type 2 Inflammation
expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

When is the right time to consider a biologic in patients with CRSwNP?
Type 2 Inflammation
expert video

When is the right time to consider a biologic in patients with CRSwNP?

How often do you suggest to assess sense of smell?
Type 2 Inflammation
expert video

How often do you suggest to assess sense of smell?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Type 2 Inflammation
expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

Exploring Neurosensitization and Pain in Prurigo Nodularis
Dermatology
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis
Dermatology
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region